Jessica Whitten

Jessica Whitten (senior executive) discloses dealings in bluebird bio, Inc. to SEC (Form 4). Over a trading history stretching from 11 November 2021 to 1 February 2022, the count stands at 5 filings.

Sales make up the whole of the open-market record (2 sales, €29k). Outside the open market, there are 2 share grants. 2022 to date brings no purchases and 2 sales.

Most recently, on 3 February 2022, the filings show a share grant in bluebird bio, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.